Panel finds a daily dose of aspirin is only effective for adults with high risk of stroke or heart attack. See which high-risk group benefits most.
ScienceDaily® recently reported about research done on the effects of rivaroxaban for preventing strokes. The XANTUS study, the results of which were published in the medical journal European Society of Cardiology, show that atrial fibrillation (AF) patients who were treated with rivaroxaban for the prevention of strokes had lower rates of bleeding and stroke.
The observational study analyzed the effectiveness of treatment with rivaroxaban in 6, 784 non-valvular AF patients in 311 different centers throughout Europe and Canada. Dosing varied according to the discretion of the doctors treating these patients. Follow-up observation was made on these patients one year after treatment. The researchers found that 96.1 percent of the patients treated did not experience major bleeding, stroke, systemic embolism or death in the year following treatment with rivaroxaban.
The study concluded that “oral anticoagulation with rivaroxaban, a direct Factor Xa inhibitor, is safe and effective for stroke prevention in patients with AF at both high- and low-risk of thromboembolic events.”
You can learn more about this study and its findings by reading the European Society of Cardiology’s press release, Low bleeding and stroke rates in AF patients given rivaroxaban for stroke prevention.
Panel finds a daily dose of aspirin is only effective for adults with high risk of stroke or heart attack. See which high-risk group benefits most.
Tactical Medicine (TM) is a discipline that specializes in the emergency medical support and services required to support the mental and physical health and the overall safety of law enforcement and military special operations (i.e., SWAT) personnel during critical incidents and training.
Comments